Literature DB >> 6627809

Interindividual variations in drug disposition. Clinical implications and methods of investigation.

D D Breimer.   

Abstract

Mesh：

Substances：

Year:  1983        PMID： 6627809     DOI： 10.2165/00003088-198308050-00001

Source DB:  PubMed          Journal:  Clin Pharmacokinet        ISSN： 0312-5963            Impact factor:   6.447


× No keyword cloud information.
  28 in total

1.  The antipyrine test in clinical pharmacology: conceptions and misconceptions.

Authors:  E S Vesell
Journal:  Clin Pharmacol Ther       Date:  1979-09       Impact factor: 6.875

Review 2.  Polymorphisms of oxidation at carbon centers of drugs and their clinical significance.

Authors:  J R Idle; R L Smith
Journal:  Drug Metab Rev       Date:  1979       Impact factor: 4.518

Review 3.  Assessment of methods to identify sources of interindividual pharmacokinetic variations.

Authors:  E S Vesell; M B Penno
Journal:  Clin Pharmacokinet       Date:  1983 Sep-Oct       Impact factor: 6.447

Review 4.  Ethnic differences in drug metabolism.

Authors:  W Kalow
Journal:  Clin Pharmacokinet       Date:  1982 Sep-Oct       Impact factor: 6.447

5.  Antipyrine kinetics in the elderly: prediction of age-related changes in benzodiazepine oxidizing capacity.

Authors:  D J Greenblatt; M Divoll; D R Abernethy; J S Harmatz; R I Shader
Journal:  J Pharmacol Exp Ther       Date:  1982-01       Impact factor: 4.030

6.  Genetic variation in rates of antipyrine metabolite formation: a study in uninduced twins.

Authors:  M B Penno; B H Dvorchik; E S Vesell
Journal:  Proc Natl Acad Sci U S A       Date:  1981-08       Impact factor: 11.205

7.  Induction of hexobarbital and antipyrine metabolism by rifampicin treatment in the pig.

Authors:  J M van den Broek; M W Teunissen; D D Breimer
Journal:  Drug Metab Dispos       Date:  1981 Nov-Dec       Impact factor: 3.922

8.  E- and Z-10-hydroxylation of nortriptyline: relationship to polymorphic debrisoquine hydroxylation.

Authors:  B Mellström; L Bertilsson; J Säwe; H U Schulz; F Sjöqvist
Journal:  Clin Pharmacol Ther       Date:  1981-08       Impact factor: 6.875

9.  3-Hydroxymethyl antipyrine excretion in urine after an oral dose of antipyrine. A reconsideration of previously published data and synthesis of a pure reference substance.

Authors:  M Danhof; M W Teunissen; D D Breimer
Journal:  Pharmacology       Date:  1982       Impact factor: 2.547

10.  Comparison of the in vivo and in vitro rates of formation of the three main oxidative metabolites of antipyrine in man.

Authors:  A R Boobis; M J Brodie; G C Kahn; E L Toverud; I A Blair; S Murray; D S Davies
Journal:  Br J Clin Pharmacol       Date:  1981-12       Impact factor: 4.335
View more
  41 in total

Review 1.  Drug-induced agranulocytosis: review of possible mechanisms, and prospects for clozapine studies.

Authors:  F H Claas
Journal:  Psychopharmacology (Berl)       Date:  1989       Impact factor: 4.530

2.  Pharmacokinetics of adriamycin, adriamycinol, and antipyrine in patients with moderate tumor involvement of the liver.

Authors:  R Preiss; M Matthias; R Sohr; B Brockmann; H Hüller
Journal:  J Cancer Res Clin Oncol       Date:  1987       Impact factor: 4.553

3.  Elimination of cotinine from body fluids.

Authors:  D W Sepkovic; N J Haley
Journal:  Am J Public Health       Date:  1988-06       Impact factor: 9.308

4.  Urinary excretion of 6 beta-hydroxycortisol and the time course measurement of enzyme induction in man.

Authors:  E E Ohnhaus; A M Breckenridge; B K Park
Journal:  Eur J Clin Pharmacol       Date:  1989       Impact factor: 2.953

5.  Evaluation of infusion regimens for thiopentone as a primary anaesthetic agent.

Authors:  D P Crankshaw; N E Edwards; G L Blackman; M D Boyd; H N Chan; D J Morgan
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953

6.  Antipyrine metabolite formation and excretion in patients with chronic renal failure.

Authors:  M W Teunissen; D Kampf; I Roots; N P Vermeulen; D D Breimer
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953

7.  Obesity effects on nitrazepam disposition.

Authors:  D R Abernethy; D J Greenblatt; A Locniskar; H R Ochs; J S Harmatz; R I Shader
Journal:  Br J Clin Pharmacol       Date:  1986-11       Impact factor: 4.335

8.  Influence of cimetidine on steady state concentration and metabolite formation from antipyrine infused with a rectal osmotic mini pump.

Authors:  M W Teunissen; C H Kleinbloesem; L G de Leede; D D Breimer
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953

9.  The relationship between phenazone (antipyrine) metabolite formation and theophylline metabolism in healthy and frail elderly women.

Authors:  K Groen; M A Horan; N A Roberts; R S Gulati; B Miljkovic; E J Jansen; V Paramsothy; D D Breimer; C F van Bezooijen
Journal:  Clin Pharmacokinet       Date:  1993-08       Impact factor: 6.447

10.  The metabolism of 17 alpha-ethinyloestradiol by human liver microsomes: formation of catechol and chemically reactive metabolites.

Authors:  H S Purba; J L Maggs; M L Orme; D J Back; B K Park
Journal:  Br J Clin Pharmacol       Date:  1987-04       Impact factor: 4.335
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.